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rug-Eluting Stenting
or Unprotected Left
ain Coronary Artery Disease
re We Ready
o Replace Bypass Surgery?*
onald S. Baim, MD, FACC,
aura Mauri, MD, MS,
onald C. Cutlip, MD, FACC
oston, Massachusetts
t has been five years since our last editorial in the Journal
egarding the role of stenting in the treatment of unpro-
ected left main coronary artery disease. In the intervening
ime, the landscape of coronary stenting has changed
ramatically. In particular, the advent of drug-eluting stents
DES) in mid-2003 has pushed the rate of clinical restenosis
elow 5% for most lesion types (1,2). The effect of such low
estenosis rates has reduced the one-year repeat revascular-
zation rate for multivessel disease to approach that of
ypass surgery (7.4% vs. 3.7%) (3), and some estimates may
educe the need for coronary artery bypass surgery by up to
6% (4). Nevertheless, many of the questions that were
aised five years ago regarding the role of stenting versus
urgery for an unprotected left main coronary artery are still
n play.
See pages 864 and 871
Despite 25 years of progressive improvements in proce-
ural safety and long-term lesion outcomes for percutaneous
oronary intervention (PCI) (including a decade of bare-
etal stents [BMS] and three years of DES), the unpro-
ected left main has remained mostly the province of cardiac
urgery. Clinical trials conducted in the late 1970s in
atients with significant narrowing of the left main trunk
emonstrated that bypass surgery reduces the substantial
hree-year mortality seen with medical therapy (i.e., from
1% to 9%) (5). While there have been progressive improve-
ents in left main PCI over the last 20 years, no prospective
andomized trial has been performed comparing left main
CI to surgery. Accordingly, interventional cardiologists
ave generally respected this lesion as one of the last
astions of surgical dominance, given concerns about high
cute procedural risk or poor long-term durability (i.e., reste-
osis, which in this anatomic location may present as either
ecurrent angina or sudden death).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or ther
merican College of Cardiology.
From the Harvard Clinical Research Institute (HCRI), Boston, Massachusetts.Still, progressive interventional forays into this area have
een made, first in patients with left main lesions “pro-
ected” by a patent bypass graft to the left anterior descend-
ng or circumflex, and then in patients with unprotected left
ain lesions whose other underlying conditions made them
oor candidates for surgery. These experiences showed that
he earlier concerns about acute safety of left main PCI were
argely unfounded; despite fears that even temporary left
ain occlusion during balloon inflation would lead to
emodynamic collapse, even the early balloon angioplasty
xperience showed that patients with good baseline left
entricular function can tolerate left main angioplasty with-
ut hemodynamic support. The fear of lethal dissection and
brupt closure of the left main has similarly been allayed by
he dominance of stenting, first as a bail-out and then as
preemptive treatment. In contrast, concerns about the
urability of the initial result have yielded more gradually.
urability for unprotected left main balloon angioplasty was
oor, with 30% one-year mortality (6). Coronary stenting
mproved both acute results and restenosis rates compared
ith balloon angioplasty, as demonstrated by several groups
n the late 1990s (7–12). Repeat revascularization rates,
owever, remained 25% to 30% (about two-thirds repeat
CI and one-third coronary artery bypass grafting
CABG]), with substantial one-year mortality (up to 30% in
ome series).
What became clear, however, was that the observed
n-hospital and one-year mortality depended strongly on
atient selection, being as high as 78% in patients with poor
eft ventricular function and acute ischemic syndromes, and
s low as 3.4% in patients without such high-risk markers
who made up 32% of the Unprotected Left Main Trunk
ntervention Multicenter Assessment [ULTIMA] registry)
11). Similarly, it became clear that the restenosis risk for
are-metal stenting was influenced significantly by lesion
ocation, lowest when the left main lesion was confined to
he ostium or mid-shaft, higher if it involved the distal
ifurcation (restenosis rate 23% overall), and higher still if
ultiple stent approaches to the distal bifurcation (T, V,
ulotte, or crush) were used. Enthusiasm about left main
tenting thus continued to be tempered by the high reste-
osis risk, and the recognition that unrecognized and,
herefore, untreated restenosis of the left main may present
s sudden cardiac death (7).
With the availability of DES and the dramatic reduction
n restenosis rates they provide, the results of left main
tenting have improved further. Several recent registry
eports (13–15) have demonstrated excellent acute proce-
ural results (although mostly restricted to patients with
ood left ventricular function). Restenosis has been rare for
stial and mid-shaft lesions, but it has been significantly
igher (8% to 17%) for distal left main lesions, especially
ith the two-stent techniques (Table 1). Indeed, the Park et
l. (14), Chieffo et al. (15), and Valgimigli et al. (13)
egistries demonstrated that restenosis after left main drug-
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February 21, 2006:878–81 Editorial Commentluting stenting was essentially confined to distal bifurcation
esions. The ostium of the left circumflex is a particular
ssue, accounting for about one-half of the restenosis cases
n these series. In our own experience, there have also been
everal cases of stent fracture in the circumflex simultaneous
issing stent at the bend leaving the left main, resulting in
evere focal restenosis at this location.
The same pattern seen in other bifurcation lesions is also
vident in the left main bifurcation—placement of a single
tent across the circumflex (with balloon angioplasty rescue
f required) seems to offer results at least as satisfactory as
ny of the current two-stent techniques (16). But the
urrently available left main DES series clearly shows lower
arget vessel revascularization rates than the BMS data from
he same operators. In addition, most repeat revasculariza-
ions require only repeat PCI, with a 6- to 12-month
ortality rate (2% to 4% excluding patients in cardiogenic
hock) that remains acceptably low. This begs the question of
hether these improved short- and intermediate-term outcomes
ow make drug-eluting stenting a viable alternative to bypass
urgery in patients with left main stenosis.
This issue of the Journal contains two non-randomized
tudies of drug-eluting stenting of the left main coronary
rtery that help to place this question in sharper focus. Lee
t al. (17) compared 50 consecutive patients undergoing
CI for unprotected left main coronary stenoses to a
onsecutive series of 123 patients undergoing CABG during
he same time period. Most lesions (60%) were located at
he distal left main bifurcation and were treated with one of
able 1. Summary of Drug-Eluting Stent Studies for Unprotecte
Park et al. (14) Chieffo et al.
102 85
istal location, n (%) 72 (71) 69 (81)
istal stent technique
Single (across circumflex), n 43 8
T or Culotte, n 1 9
SKS or V-stent, n 17 12
“Crush” technique, n 11 30
ardiac mortality 12 months (0%) 6 months (3.
ngiographic restenosis
Overall, n (%) 6/86 (7.0) 12 (14.1)
Distal lesions, n 6 12
Single stent, n 1 0
T or Culotte 0 3
SKS or V-stent, n 3 1
“Crush” technique, n 2 8
stial circumflex restenosis
location, n
4 5
arget lesion revascularization
Overall, n (%) 2 (2.0) 11 (12.9)
Distal lesions, n 0 11
Single stent, n 0 0
T or Culotte 0 3
“Kissing” stents, n 2 1
“Crush” technique, n 0 7
Numbers calculated from percentages provided; †all deaths within 30-days occurr
ischemia-driven 9 (18%).
SKS  simultaneous kissing stents.everal two-stent techniques (crush, kissing, or T stenting). ihe rate of acute procedural success was 98% for PCI, and
0-day mortality was low (2% for PCI vs. 5% for CABG,
 NS) despite a somewhat higher clinical risk profile.
ith six-month follow-up, the PCI cohort continued to
ave a non-significantly better survival compared with the
urgical cohort (96% vs. 87% at six months), with higher
omposite freedom from death, myocardial infarction, ur-
ent target vessel revascularization, and adverse cerebrovas-
ular events (83% vs. 75% at one year). However, systematic
urveillance for myocardial infarction by routine lab evalu-
tion was not performed post-procedure, angiographic
ollow-up was incomplete (only 42% after PCI), and clinical
ollow-up (reported overall mean six months) was nearly
ne month shorter for the PCI than the CABG cohort,
aising concerns about whether these end points were
ompletely ascertained. Moreover, the freedom from repeat
evascularization remained higher for the surgical cohort
ompared to the PCI cohort (95% vs. 87% at one year),
lthough all repeat procedures were performed percutane-
usly. These data are echoed by the Milan experience, with
ower 1-year mortality (2.8% vs. 6.4%) but higher target
esion revascularization (15.8% vs. 3.6%), for drug-eluting
tenting versus CABG of unprotected left main stenosis
18).
Price et al. (19) present additional data in this issue about
he angiographic follow-up of DES-treated left main le-
ions. This 50-patient registry consists predominantly of
istal bifurcation lesions (94%), treated using the kissing
tent technique. Technical success was uniform, and no
ft Main
Valgimigli et al. (13) Lee et al. (17) Price et al. (19)
95 50 50
62 (65) 30 (60) 47 (94)
37* 10 4
20 3 0
2 5 34
3 12 8
12 months (11.0%)† 12 months (4%) 12 months (2%)
Not reported Not reported 21 (44)
Not reported
1 Not reported 15
6 (6.3) 5 (10) 19 (38)‡
6 5 18
3 Not reported
2 Not reported
0 Not reported 13
1 Not reported 5
patients with ST-segment elevation myocardial infarction and cardiogenic shock;d Le
(15)
5%)
ed inn-hospital deaths occurred despite a more complex patient
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Editorial Comment February 21, 2006:878–81ix. There were two acute stent thromboses (both with
issing stents) and five deaths at one year (although only one
ppears to have been cardiac). The concern, however, lies in
he follow-up angiography, which was performed at three
nd nine months (94% and 90% compliance among eligible
atients). It showed angiographic restenosis in 23% in the
eft main to left anterior descending coronary artery (LAD)
ocation, and 35% in the circumflex location, for an overall
ngiographic restenosis rate of 42% in any vessel (left main,
stial LAD, or ostial left circumflex artery). The combined
ate of death, myocardial infarction, repeat revasculariza-
ion, and stent thrombosis was 10% in-hospital and 44% at
median follow-up of nine months. This reflected mostly
he 19 patients (38%) who underwent target lesion revas-
ularization (18 of whom had been treated with bifurcation
tenting), of which only 7 (14%) were ischemia-driven.
gain, all of the repeat revascularization was achieved via
epeat PCI.
With this latest round of data, it is fair to ask “Have we
nally reached the point where patients with left main
isease can be offered elective DES treatment as an alter-
ative to coronary artery bypass surgery?” There is no doubt
hat we have made further progress, that the 6- to 12-month
ortality rates of 2% to 4% are now similar to in-hospital
ortality rates reported for surgery for left main disease
20,21), and that DES-treated lesions in the ostial or
id-left main have a very low (5%) rate of angiographic or
linical restenosis with DES. In the ostial to mid-vessel
ocation, however, one limitation remains the lack of current
ES that can be expanded above 4.5 mm. A more impor-
ant limitation is that the majority of left main lesions
reated are located in the distal left main bifurcation, for
hich we still do not have an ideal stenting approach. If the
ircumflex is small or not relatively diseased, a single stent
pproach (left main into LAD, with balloon rescue of the
ircumflex if needed) has much to recommend it, but most
ases have a circumflex that is both large and diseased. None
f the current two-stent DES strategies (with a 2% stent
hrombosis rate and a 20% to 44% angiographic restenosis
ate) have been able to meet the durability standard we have
ome to expect for DES coronary revascularization. The
urrent level of restenosis thus makes it necessary to perform
outine surveillance angiography, perhaps at both three and
ine months as per the Price et al. report (19), to detect
estenosis and perform repeat PCI if restenosis is present.
ithout that safety net, one would expect an up-tick in late
ortality events resulting from unrecognized restenosis in this
ritical location.
Fortunately, novel stents are now being developed to
rovide better mechanical solutions for bifurcation lesions,
nd will rapidly be converted from bare-metal to drug-
luting status. Within the next two years, one would expect
wave of registry data regarding the use of these newer
ifurcation stents in distal left main bifurcation lesions. If
hese data are more encouraging, the time will have come to
nitiate direct randomized trials of drug-eluting stentingersus bypass surgery for even low-risk surgical candidates.
ven for the ostial and mid-left main, where greater
uccesses have been achieved with drug-eluting stenting,
ne might well require longer-term (three- to five-year) data
efore applying such a strategy to all-comers. Because the
erit of surgery for left main lesions is based mostly on
ortality reduction, a surgically equivalent mortality reduc-
ion should be demonstrated by PCI. This may be difficult
despite coronary artery bypass surgery’s higher initial mor-
ality) because over the longer term it protects against events
elated to entire zones of proximal vulnerability, thereby
educing the incidence or lethality of subsequent myocardial
nfarctions (22). While there are clearly challenges of a
andomized trial comparing surgery to PCI, such a trial
ould demonstrate non-inferiority of left main stenting in
pproximately 300 to 500 subjects.
Until such a trial is completed, however, broad elective use of
rug-eluting stenting in low-risk surgical candidates, particu-
arly the majority of that group who have distal bifurcation
esions that would warrant a two-stent approach, is probably
remature. Certainly that option can continue to be offered
o patients with anatomically suitable left main disease who
resent a higher surgical risk, as long as they accept the need
or prolonged dual antiplatelet therapy and surveillance
ollow-up angiography. With these precautions, the main
ownside will likely remain limited to a need for angio-
raphic surveillance and angiographically triggered repeat
ercutaneous interventions (plus some late bypass surgery),
ithout a surplus of late deaths and myocardial infarctions.
eprint requests and correspondence: Dr. Donald S. Baim,
righam and Women’s Hospital, 75 Francis Street, Boston,
assachusetts 02115. E-mail: dbaim@partners.org.
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